GSK‐J4 is an effective dual inhibitor of H3K27me3/me2 demethylases KDM6B and KDM6A, known to promote gene silencing and cell apoptosis by inhibiting KDM6A to regulate histone methylation levels, with applications in cancer treatment. The gene discussed is KDM6A; the disease is cancer.